About 60 percent of all cancer patients in the United States receive radiation therapy as part of their treatment.

ImmunoPrecise Antibodies Ltd., an AI-powered antibody company, has partnered with RIBOPRO, a technology provider specializing ...

This approach could transform radiation therapy by allowing higher doses to be used more safely, ultimately improving outcomes for cancer patients.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and ...

About 60% of all cancer patients in the United States receive radiation therapy as part of their treatment. However, this ...